The clinical efficacy of immune checkpoint inhibitors depends on the presence of tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) in cancer patients, and the basic principle is to utilize the patient's own CTLs [3]. The gene discussed is CD8A; the disease is neoplasm.